

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

End of Result Set

☐ [Generate Collection](#) [Print](#)

L6: Entry 42 of 42

File: DWPI

Feb 1, 1994

DERWENT-ACC-NO: 1994-074816

DERWENT-WEEK: 199410

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Sustained release compsn. for oral treatment of Alzheimer's disease -
comprises particles of galanthamine coated with layers of polyvinyl pyrrolidone

INVENTOR: DAVIS, B; GOODMAN, M

PRIORITY-DATA: 1988CA-0581365 (October 26, 1988)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> CA 1326632 C	February 1, 1994		004	A61K031/55

INT-CL (IPC): A61K 9/22; A61K 9/52; A61K 31/55

ABSTRACTED-PUB-NO: CA 1326632C

BASIC-ABSTRACT:

Sustained release formulation for oral admin. in the form of a tablet or capsule for treatment of Alzheimer's disease and related dementias comprises particles of galanthamine (I) (or its salt) which are coated with a coating agent (II), which is soluble in the intestinal tract. The thickness of the coatings varies between individual particles and the particles have various coating thicknesses chosen so as to result, after admin., in release of the drug from its coated particles at different times.

The particles comprises galanthamine hydrobromide (II) is polyvinyl pyrrolidone.

The tablets or capsules pref. comprise 25-250 mg of active cpd.. The daily dosage is 10-2000 mg.

USE - The formulations provide long-acting treatment of Alzheimer's disease and related dementias.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)



Generate Collection

Print

L12: Entry 32 of 35

File: USPT

Aug 17, 2004

DOCUMENT-IDENTIFIER: US 6777435 B1

TITLE: Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics

Detailed Description Text (73):

The dosage forms of a pharmaceutical composition include oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, suspensions; and non-oral preparations such as injections (e.g. subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection), drip infusions, external application forms (e.g. nasal preparations, transdermal preparations, ointments), suppositories (e.g. rectal suppositories, vaginal suppositories), pellets, solutions for instillation, sustained-release preparations.

Detailed Description Text (116):

Examples of the antidementia agent include tacrine, donepezil, rivastigmine, galantamine.

Detailed Description Text (152):

A fluidized-bed granulating dryer (produced by POWREX) was charged with 576.0 g of Compound A. 2513 g of lactose, 356.4 g of corn starch and 217.8 g of croscarmellose sodium, which was admixed with preheating. Then, granulation was carried out while spraying an aqueous solution in which 138.6 g of hydroxypropylcellulose was dissolved. 3590 g of the obtained granules were milled by a Power-Mill (produced by Showa Machinery Co., Ltd.) to give pulverized powders. 3432 g of the obtained pulverized powders, 125.1 g of corn starch and 17.88 g of magnesium stearate were admixed in a tumble mixer (produced by Showa Machinery Co., Ltd.). 3410 g of the obtained mixed powders were tableted with a tableting machine (produced by Kikusui Seisakusho Co., Ltd.) to give plain tablets.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)